Expression of ras, c-myc, and p53 proteins in cervical intraepithelial neoplasia

Cancer

Volumn 83, Issue 7, 1998, Pages 1401-1408

  Slagle, Betty L ^a   Kaufman, Raymond H ^a   Reeves, William C ^b   Icenogle, Joseph P ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

C myc; Cervical carcinoma; P53; Ras; Tumor suppressor

Indexed keywords

MYC PROTEIN; PROTEIN P53; RAS PROTEIN;

ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER;

CARCINOMA IN SITU; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0032188831     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981001)83:7<1401::AID-CNCR18>3.0.CO;2-8     Document Type: Article

References (43)

1. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papilloma virus types. Curr Topics Microbiol Immunol 1994;186:131-56.
2. Schiffman MJ. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84:394-7.
3. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 1993;7:872-9.
4. Ambros RA, Kurman RJ. Current concepts in the relationship of human papillomavirus infection to the pathogenesis and classification of precancerous squamous lesions of the uterine cervix [review]. Semin Diagn Pathol 1990;7:158-72.
5. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate cancer. Cancer Res 1992; 52:5991-6.
6. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-14.
7. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O, Rice JM. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 1990;50:6139-45.
8. Sagae S, Kudo R, Kuzumaki N, Hisada T, Mugikura Y, Kudo R, et al. Ras oncogene expression and progression in intraepithelial neoplasia of the uterine cervix. Cancer 1990; 2:295-301.
9. Pinion SB, Kennedy JH, Miller RW, MacLean AB. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix. Lancet 1991;337:819-20.
10. Hayashi Y, Hachisuga T, Iwasaka T, Fukuda K, Okuma Y, Yokoyama M, et al. Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 1991;40:147-51.
11. Agnantis NJ, Mahera H, Maounis N, Papanicolaou A, Spandidos DA. ras p21 oncoprotein: expression in human cervical intraepithelial neoplasias and other benign conditions of the uterine cervix. Adv Applied Biotechnol Ser 1990;6:97-101.
12. Crook T, Wrede D, Tidy J, Scholefield J, Crawford L, Vousden KH. Status of c-myc, p53, and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene 1991;6:1251-7.
13. Lazo PA, DiPaolo JA, Popescu NC. Amplification of the integrated viral transforming genes of human papillomavirus 18 and its 5'-flanking cellular sequence located near the myc protooncogene in HeLa cells. Cancer Res 1989;49:4305-10.
14. Shirasawa H, Tomita Y, Sekiya S, Takamizawa H, Simizu B. Integration and transcription of human papillomavirus type 16 and 18 sequences in cell lines derived from cervical carcinomas. J Gen Virol 1987;68:583-91.
15. Durst M, Croce CM, Gissmann L, Schwarz E, Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 1987; 84:1070-4.
16. Riou GF, Bourhis J, Le MG. The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer [review]. Anticancer Res 1990;10:1225-31.
17. Ocadiz R, Sauceda R, Cruz M, Grauf AM, Gariglio P. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 1987;47:4173-7.
18. Gotoh M, Nakajima T, Yokota J, Tsunokawa Y, Terada M, Shimoyama Y, et al. Newly established uterine cervical carcinoma cell line with co-amplification of human papillomavirus DNA and c-myc gene. Jpn J Cancer Res 1991;82:1252-7.
19. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
20. Kaufman RH, Adam E, Icenogle J, Lawson H, Lee N, Reeves WC, et al. Relevance of HPV screening in management of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1997; 176:87-92.
21. Li Y, Seyama T, Godwin AK, Winokur TS, Lebovitz RM, Leiberman MW. MTras, a metallothionein -ras fusion gene, modulates expression in cultured rat liver cells of two genes associated with in vivo liver cancer. Proc Natl Acad Sci USA 1988;85:344-8.
22. Birnie GD. The HL60 cell line: a model system for studying human myeloid cell differentiation. Br J Cancer 1988;9 (Suppl):41-5.
23. Unger ER, Brigate DJ, Chenggis ML, Budgeon LR, Koebler D, Cuomo C, et al. Automation of in situ hybridization: application of the capillary action robotic workstation. Histotech 1988;11:253-8.
24. van den Berg FM, Baas IO, Polak MM, Offerhaus GJ. Technical and methodologic advances: detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol 1993;142:381-5.
25. Gulbis B, Galand P. Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors [review]. Hum Pathol 1993;24:1271-85.
26. Sagae S, Kuzumaki N, Hisada T, Mugikura Y, Kudo R, Hashimoto M. ras oncogene expression and prognosis of invasive squamous cell carcinomas of the uterine cervix. Cancer 1989;63:1577-82.
27. Riou G, Sheng ZM, Zhou D, Barrois M. C-Ha-ras and c-myc proto-oncogenes in cervical cancers: prognostic interest. In: Bolla M, Chambaz EM, Vrousos C, editors. Growth factors and oncogenes. Montrouge, France: John Libbey Eurotext Ltd., 1995:173-82.
28. Bernard C, Mougin C, Laurent R, Lab M. Oncogene activation: an informative marker for the human papillomavirus-lesions severity. Cancer Detect Prev 1994;18:273-82.
29. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
30. Jiko K, Tsuda H, Sato S, Hirohashi S. Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. Int J Cancer 1994;59:601-6.
31. Tervahauta AK, Syrjanen SM, Vayrynen M, Saastamoinen J, Syrjanen KJ. Expression of p53 protein related to the presence of human papillomavirus (HPV) DNA in genital carcinomas and precancer lesions. Anticancer Res 1993;13:1107-12.
32. Pollanen R, Soini Y, Vahakangas K, Paakko P, Lehto VP. Aberrant p53 protein expression in cervical intra-epithelial neoplasia. Histopathology 1993;23:471-4.
33. Walts AE, Koeffler HP, Said JW. Localization of p53 protein and human papillomavirus in anogenital squamous lesions: immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia. Hum Pathol 1993;24:1239-42.
34. Oka K, Nakano T, Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993;72:160-4.
35. DiPaolo JA, Woodworth CD, Popescu NC, Notario V, Doniger J. Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene 1989;4:395-9.
36. Willis G, Jennings B, Ball RE, New NE, Gibbon I. Analysis of ras point mutations and human papillomavirus 16 and 18 in cervical carcinomata and their metastases. Gynecol Oncol 1993;49:359-64.
37. Tate JE, Mutter GL, Prasad CJ, Berkowitz R, Goodman H, Crum CP. Analysis of HPV-positive and -negative vulvar carcinomas for alterations in c-myc, Ha-, Ki-, and N-ras genes. Gynecol Oncol 1994;53:78-83.
38. Falcinelli C, Luzi P, Alberti P, Cosmi EV, Anceschi MM. Human papilloma virus infection and Ki-ras oncogene in paraffin-embedded squamous carcinomas of the cervix. Gynecol Obstet Invest 1993;36:185-8.
39. Van Le L, Stoerker J, Rinehart CA, Fowler WC. H-ras codon 12 mutation in cervical dysplasia. Gynecol Oncol 1993;49: 181-4.
40. Couturier J, Sastre-Garau X, Schneider-Maunoury S, Labib A, Orth G. Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J Virol 1991;65:4534-8.
41. Akasofu M, Oda Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. Virchows Arch 1995; 425:593-602.
42. Vecchione A, Cermele C, Giovagnoli MR, Valli C, Alimandri M, Carico E, et al. p53 expression and genetic evidence for viral infection in intraepithelial neoplasia of the uterine cervix. Gynecol Oncol 1994;55:343-8.
43. Huibregtse JM, Scheffner M, Howley PM. E6-AP directs the HPV E6-dependent inactivation of p53 and is representative of a family of structurally and functionally related proteins. Cold Spring Harb Symp Quant Biol 1994; 59:237-46.